Nano Nuclear Energy

Phase A — Understand the business

Company Overview

NANO Nuclear Energy Inc. (Nasdaq: NNE; Nevada incorporated; HQ 10 Times Square, NYC) is a pre-revenue advanced-nuclear developer that IPO'd in May 2024 and is building a vertically integrated position across the microreactor value chain. Management runs four business lines, none yet commercial:

1. Nuclear Reactor Business (the core). Lead program is the KRONOS MMR™ — a ~15 MWe high-temperature gas-cooled reactor (HTGR) using TRISO fuel and helium coolant, acquired (with the LOKI MMR™ portfolio) out of the Ultra Safe Nuclear Corporation (USNC) Chapter 11 bankruptcy for $8.5M cash in January 2025. USNC is publicly believed to have spent >$120M developing KRONOS — a striking asset-value arbitrage. The KRONOS demonstration reactor is being built with the University of Illinois Urbana-Champaign (UIUC). Portfolio also holds LOKI MMR™ (portable HTGR), ZEUS™ (solid-core "nuclear battery"), and ODIN™ (low-pressure coolant reactor, being sold — see below). Commercial launch targeted early 2030s.
2. Fuel Processing Business. Subsidiary HALEU Energy Fuel Inc.; a founding member of the DOE HALEU Consortium; aims to build domestic LEU/HALEU fuel-cycle facilities. Anchored on a $2M investment in LIS Technologies (LIST) — a related-party laser-enrichment company — with which NNE was named one of six awardees in the DOE's $3.4B LEU Acquisition Program (LIST prime, NNE subcontractor). Target launch 2026.
3. Fuel Transportation Business. Exclusive BEA License (April 2024) for a high-capacity HALEU transport-basket design; study agreement with Germany's GNS. Target launch by 2028.
4. Nuclear Consultation Services. The "nearest-term revenue opportunity"; generated a token $250K consulting fee from Digihost (Apr–Jun 2025).

Contract structure / payment terms: essentially none yet — there are no take-or-pay contracts, no recurring revenue, no backlog. Revenue to date is a $250K consulting fee plus small lease income; "customers" are collaborators (UIUC), national labs (INL, ORNL, PNNL), and MOU counterparties (Supermicro), not paying buyers. The nearest thing to a commercial contract is the ODIN sale to Cambridge Atom Works (UK) for $6.2M ($250K down + $5.95M in 2026 + royalties).

Plain-terms: NNE is a well-funded call option on being first through NRC microreactor licensing, wrapped in a four-legged "vertically integrated fuel cycle" story. It sells narrative and milestones today; it hopes to sell electrons and fuel in the 2030s.

Supply Chain

Map the intended chain — every node is aspirational; NNE owns almost none of it yet:

• Uranium (upstream): MOU with UrAmerica Ltd. for uranium offtake/mining in Chubut Province, Argentina (non-binding). No owned mine.
• Conversion → enrichment (HALEU): dependent on LIS Technologies (LIST) laser enrichment (related party, pre-commercial) and the DOE $3.4B LEU Acquisition Program. NNE intends to build "back-end" deconversion/fabrication alongside LIST's future enrichment plant. Single-source dependency on a related, pre-revenue enrichment startup is the central supply-chain chokepoint.
• Fuel fabrication: to be built by HALEU Energy Fuel Inc.; site "tentatively identified," not built.
• Reactor components: high-temperature alloys, TRISO fuel, precision reactor structures — explicitly flagged as supply-constrained; NNE leans on national labs (INL, ORNL, PNNL) via a 10-year INL CRADA and a DOE GAIN voucher (with ORNL) for KRONOS uncertainty-quantification work.
• Engineering / EPC: AECOM master services agreement for UIUC site engineering & environmental work; aRobotics for the Westchester demo-facility build-out.
• Transport: BEA-licensed HALEU basket + GNS package study; two ex-executives of "the largest shipping company in the world" and a former UPS executive advising.
• End customers (intended): data centers (Supermicro MOU), remote/mining/island communities, defense/military bases, DOE/national labs, and — via LOKI — NASA lunar/space (RFI issued 2026).

Chokepoints: (1) HALEU fuel supply — the entire advanced-reactor industry is short HALEU, and NNE's answer is a related-party startup (LIST); (2) NRC licensing throughput (first-of-a-kind); (3) TRISO fuel qualification. This lens is honest about names but thin on ownership — NNE is an integrator of MOUs, licenses, and lab relationships, not yet an operator of any link in the chain.

Competitive Advantages (moats)

Claimed moats, graded:

• "Only vertically integrated microreactor company" — the marquee claim: reactor + fuel + transport + consulting under one roof. Real if executed, unproven today — every leg is pre-commercial, so the "integration" is a slide, not a moat.
• KRONOS IP + first-mover licensing. The strongest genuinely differentiating asset: NNE holds 38 patents + 16 trademarks from USNC and, critically, the first microreactor construction-permit application (CPA) formally accepted by the NRC (May 18, 2026). First-through-the-gate on NRC microreactor licensing is a durable, hard-to-replicate advantage if the permit is granted — a fee-exempt research reactor at UIUC is a clever low-friction path.
• National-lab + government relationships. INL 10-year CRADA, DOE HALEU Consortium founding member, DOE LEU program awardee, GAIN voucher, plus hires of ex-NRC and ex-DOE senior staff (Eric Oesterle, David Tiktinsky, John Vonglis). Regulatory-relationship capital is a modest, real moat in this industry.
• Balance sheet as a moat. ~$569M liquidity, debt-free (Lens 5) — in a sector where most pre-revenue peers face constant financing risk, NNE can simply outlast. This is arguably its most reliable competitive edge right now.

Bargaining power: essentially none over suppliers (needs HALEU more than anyone will need it), and none over customers (no product to sell; MOUs are non-binding). Its leverage is over capital markets — it has repeatedly raised large sums at premium valuations. Verdict on moat: a real first-mover licensing/IP seed + a fortress balance sheet, wrapped in an as-yet-unbuilt integration story. Grounding note: commercial-layer files (bottlenecks.md, positioning.md) are absent for the energy topic, so this lens leans on filings + web.

Segments

No reportable revenue segments exist — the company is consolidated pre-revenue. The only meaningful "segmentation" is spend by activity, which is the truest read of where the company actually is:

The mix is shifting in the right direction. In the six months to March 31, 2026, R&D rose to $11.06M (from $7.62M YoY) while G&A fell to $15.48M (from $18.19M YoY) — money is rotating out of SBC-heavy overhead and into actual reactor development. Geographically, spend is US (NY, Oak Ridge TN, Oak Brook/UIUC IL) with a Canadian arm (True North Nuclear / Chalk River) and UK/German outsourced engineering.

---

Phase B — Measure performance

Adapted: for a pre-revenue name, "performance" = burn, runway, dilution, and milestone velocity, not revenue beats.

Earnings Result (latest print: Q2 FY2026, quarter ended March 31, 2026)

There is no revenue line to beat or miss. The scoreboard is the balance sheet and the burn:

• Net loss: Q2 FY26 ($9.18M) vs Q2 FY25 ($21.31M); six-month FY26 ($15.70M) vs ($24.42M) YoY — losses are narrowing, driven by lower SBC and by $9.96M of interest income on the cash pile (6-mo).
• Loss from operations: 6-mo FY26 ($25.63M) ≈ flat vs ($26.41M) YoY.
• Cash & liquidity (Mar 31, 2026): cash $197.68M + short-term investments $371.00M + marketable securities $0.22M = ~$568.9M total liquidity; working capital $565.7M.
• Balance sheet: total assets $603.9M, total liabilities $8.03M (leases + payables — no debt), stockholders' equity $595.9M, accumulated deficit ($73.20M).
• Operating cash burn: 6-mo FY26 ($9.25M) → $18–20M/yr opex run-rate; PP&E grew $9.78M→$18.09M in six months ($8M capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs.) as facilities build out.
• Market reaction / what's priced in: despite the improving burn and the CPA milestone, the stock printed a fresh 52-week low (~$18–19) in July 2026, down ~68% from its $60.87 52-week high. The tape is punishing dilution and pushing out the revenue clock, not rewarding the operational progress.

Unusual vs its own history: the FY25 net loss ($40.07M) was ~47% non-cash SBC ($18.82M) — a hallmark of a promotional, equity-financed development story. That ratio is now falling. Going concern: management asserts >12 months of runway; with ~$569M and <$20M opex burn, near-term solvency is not the risk — the risk is the $300–350M-per-reactor construction bill still entirely ahead.

Earnings Calls / Communication (sentiment trend)

No earnings-call transcripts are on the research shelf, and as a smaller-reporting EGC, NNE's investor communication runs primarily through press releases and 8-K business updates rather than a rich quarterly-call cadence. Reading the communication arc:

• 2024 (post-IPO): highly promotional — aggressive timelines, a barrage of MOUs/hires, and a combative response to short-sellers (hired Quinn Emanuel / Alex Spiro to threaten Hunterbrook after its July 2024 report). Tone: defensive, litigious, narrative-forward.
• 2025: language shifts toward concrete regulatory process — NRC approval of the Fuel Qualification Methodology Topical Report (Apr 2025), the USNC/KRONOS pivot, INL CRADA, DOE GAIN voucher. Still promotional but increasingly milestone-anchored.
• 2026: the most credibility-additive stretch — CPA formally accepted by NRC (May 18), NRC review kickoff meeting (Jun 23), Supermicro AI-data-center MOU (May 6), and the dismissal of the securities class action (Jan 8, 2026) which management trumpeted.

Recurring phrases: "vertically integrated," "first-of-a-kind," "the only U.S.-origin laser enrichment," "affirm our timelines." What they've stopped saying: the earlier bravado about near-term commercial launch — the deck now leans on process milestones (permits, reviews, MOUs) rather than revenue. Net trajectory: from promoter to (still-promotional) permit-holder — a genuine, if partial, maturation.

Comps

Pre-revenue reactor developers do not support EV/Sales, EV/EBIT, P/E, dividend, or ROE — all are n/a — pre-revenue for the true peers. The honest comp is scale of the equity option and where NNE sits in the pack:

Read: among pure-play advanced-reactor developers, NNE is the smallest and cheapest by a wide margin — ~$1B cap vs Oklo's ~$9B and X-energy's ~$6B — and uniquely, ~56% of its market cap is net cash ($569M / $1.01B), so its ex-cash EV of ~$440M capitalizes the entire reactor+fuel+transport enterprise at roughly 5% of Oklo's market value. Whether that's "cheap" or "correctly discounted for being years behind" is the whole debate (Lens 12/13). Centrus and BWXT are not comps in any multiple sense — they are revenue-generating fuel/component businesses that happen to share the theme.

Stock-Price Catalysts (what actually moves NNE)

NNE has only ~2 years of trading history (IPO May 2024 at $4.00). The >5% moves cluster around narrative and dilution events, not fundamentals:

• May 2024: IPO at $4; rapid melt-up into the SMR/AI-power mania (eventual 52-week high $60.87).
• Jul 19, 2024: Hunterbrook short report ("no revenue, no products, laughable timelines, part-time executives") — stock −10% intraday, then rebounded same day.
• Late 2024–2025: repeated capital-raise / dilution events pressured the stock: Nov 2024 PIPE; May 2025 PP at $27.00; Jul 2025 $400M ATM; Oct 2025 $400M PP ($378.6M net, ~8.49M shares).
• Jan 8, 2026: securities class action dismissed — positive.
• May 6, 2026: Supermicro AI-data-center MOU — pop on the AI-power narrative.
• May 18 / Jun 23, 2026: NRC accepts and begins review of the KRONOS CPA — the highest-quality catalyst; modest reaction.
• Mar–Jul 2026: persistent drawdown to new 52-week lows ($32.93 Mar'25 → $21.10 Mar'26 → ~$19.40 Jul'26) as dilution (+43% shares YoY) and a decade-long revenue horizon outweighed the milestones.

Pattern: NNE trades as a high-beta thematic vehicle — it rips on sector euphoria (Trump nuclear EOs, White House space-nuclear mandate, AI-data-center deals) and bleeds on dilution and time. The market reacts far more to narrative catalysts and share issuance than to the (genuinely improving) operational metrics. This is a sentiment/positioning stock, not yet a fundamentals stock.

---

Phase C — Judge people & books

Management

• Jay Jiang Yu, 45 — Founder, President, Secretary, Treasurer, Chairman. Owns ~21.37% (Dec 16, 2025). Background is capital markets / junior mining promotion, not nuclear ops — concurrently chairman/president of LIST, chairman of a mineral-exploration company, CEO of an investment entity since 2008. Controls the company and its narrative.
• James Walker, 42 — CEO & Director (since 2022). 17+ years engineering PM; UK Ministry of Defence nuclear program 2013–2016 (real nuclear-lifecycle credential); but also senior exec at "Ares," and a director of Canadian small-cap miners Bayhorse Silver (BHS) and Xander Resources (XND), and a LIST consultant. The MoD nuclear background is legitimate; the small-cap-board footprint fed the short thesis.
• Jaisun Garcha, 45 — CFO (since 2022). Also part-time CFO/director at LIST; former CFO of Snipp Interactive and a mining-exploration company — an engaged-on-many-boards profile.
• Dr. Florent Heidet, 40 — CTO & Head of Reactor Development (since Mar 6, 2025). 18+ years nuclear (Argonne-caliber reactor physics) — the single strongest technical hire, but arrived only in 2025.
• Government bench: ex-DOE CFO John Vonglis, ex-NRC branch chief Eric Oesterle, 40-yr NRC veteran David Tiktinsky, ex-DOE data officer Dr. Seth Berl (board).

Track record: as a company, the team's real accomplishment is capital formation — from a $4 IPO to ~$569M in the bank and a first-of-kind CPA in under two years is genuinely impressive execution on financing and regulatory positioning. They have built no reactor and delivered no revenue. Capital allocation: the $8.5M USNC-asset purchase (for ~$120M of sunk R&D) was a genuinely shrewd distressed buy; the offsetting concern is chronic, large dilution (+43% shares/yr) and heavy SBC (FY25 $18.8M). Red flags (material): (1) pervasive related-party entanglement with LIST — Yu, Garcha, Law all hold LIST roles while NNE invests in and subcontracts to it; (2) the Yu Option Agreement routing Canadian "Consent Assets" through Yu-controlled entities; (3) two executives engaged as independent contractors with time split across multiple companies; (4) 10b5-1 selling plans set up Sept 23, 2025 (Yu up to ~3.0M shares, Walker ~409K, Garcha ~112K, Law ~131K) right around the capital-raise peak. Archetype: a promoter-founder + capital-markets machine bolted onto a national-lab-sourced technical core — effective at funding and positioning, structurally conflicted, and unproven as reactor operators.

Forensic Red Flags

Accounting quality (income statement / balance sheet / cash flow):

• SBC flatters nothing but inflates the loss and dilutes relentlessly — FY25 equity comp $18.82M = 47% of net loss. Watch APIC: it ran $49.0M → $280.1M → $669.1M across FY24→FY25→Q2'26 — the equity base has ~13×'d in under two years.
• In-process R&D of $9.08M (USNC assets) capitalized on the balance sheet — an indefinite-lived intangible that is an impairment candidate if KRONOS licensing stalls.
• Contingent consideration (ALIP) marked-to-model against NNE's own stock price each quarter — a small, benign but subjective line ($1.07M at Q2'26).
• Related-party asset: the $2.0M LIST "long-term investment, related party" sits on the books; the entire fuel-cycle strategy depends on this related, pre-revenue entity.
• Cash vs earnings: no divergence concern — with no revenue, there are no receivables/inventory games; the ~$569M is in cash + short-term investments (T-bills), and interest income is real. The books are clean but immature; the risk is governance and dilution, not fraud-style accounting.

Regulatory findings (required):

• SEC EDGAR EFTS (LR + AAER): No Litigation Releases and no AAERs naming Nano Nuclear Energy, 2021-07-10 → 2026-07-10.
• 10-K Item 3 (Legal Proceedings) — the company's own disclosure: (a) Yvette Yang v. Nano Nuclear Energy — putative securities class action, SDNY, filed Aug 9, 2024; lead plaintiff Hongyu Xie; defendants the Company, Jay Yu, James Walker, Jaisun Garcha; §10(b)/§20(a) claims for the class period May 8–Jul 30, 2024 (immediately post-IPO), attacking statements about microreactor and fuel-manufacturing progress. (b) William Latza derivative suit, Nevada state court, Aug 23, 2024 — breach of fiduciary duty, corporate waste, market manipulation, racketeering.
• Non-SEC enforcement (web search): no FTC/DOJ/FDA/CFPB/NRC/DOE enforcement action, fine, subpoena, or consent decree found.
• Material UPDATE since the 10-K: the securities class action was DISMISSED — court order Jan 8, 2026, all claims against all defendants — and the derivative suit was dismissed (April 2025). Both litigation overhangs identified at the 10-K are now resolved at the trial-court level (dismissals may be subject to appeal). This meaningfully de-risks the governance-litigation tail — though the underlying related-party structures that provoked the suits remain in place.

Summary: no SEC enforcement history; clean-but-immature accounting; the real forensic issues are dilution, SBC, related-party (LIST) dependence, and a now-dismissed post-IPO securities suit — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-07-10.

---

Phase D — Project & stress-test

Forward Projection (adapted: runway-to-catalyst, not EPS)

An EPS projection is not meaningful — NNE guides to no meaningful revenue until the early 2030s. EPS stays negative across the next three fiscal years (FY26–FY28) in every scenario; the analytically useful projection is cash runway vs the capital wall:

• Liquidity now (Mar 31, 2026): ~$568.9M, debt-free.
• Opex burn: ~$18–20M/yr and holding; interest income (~$18–20M/yr at ~3.5% on $569M) roughly offsets cash opex. On operations alone, runway is effectively open-ended (10+ years).
• The real number: management estimates $300–350M per prototype KRONOS reactor at UIUC and in Canada. That is the capital wall — and it lands as construction begins (targeted H2 2027+).

Scenarios (framed on milestone + dilution, all inputs labeled):

• Base: CPA review proceeds; NNE funds one prototype via existing cash + the $900M shelf / $400M ATM, diluting a further ~20–40% by 2028. Still pre-revenue at FY28; equity value tracks milestone de-risking and sector sentiment. Net loss widens toward ~$50–70M/yr as construction ramps.
• Bull: CPA granted (H2 2027), a binding data-center/defense offtake converts an MOU, and consulting/ALIP throw off first real (small) revenue in 2026–2027 — re-rates the ~$440M EV materially higher on "first microreactor under construction in the US."
• Bear: NRC review slips or adds scope, HALEU/LIST stalls, sector sentiment rolls over — the market keeps compressing the story toward net cash (~$10.9/share), i.e. downside toward the ~$11 net-cash floor.

No Brier forecast logged (watchlist rule + pre-revenue; no scoreable EPS line to commit).

Bull vs Bear

Bull case (narrative). NNE is the cheapest, best-capitalized way to own first-of-a-kind US microreactor licensing. It holds the only NRC-accepted microreactor construction-permit application, bought a $120M reactor program for $8.5M, sits on ~$569M of debt-free cash (≈56% of its market cap), just shed its securities-litigation overhang, and is levered to the three biggest tailwinds in energy — AI-data-center power (Supermicro MOU), the Trump administration's quadruple-nuclear mandate, and DOE's HALEU/LEU build-out. If the UIUC permit is granted, NNE becomes "the company building the first microreactor in America" — a story that can support a multiple of today's ~$440M EV. The balance sheet means it cannot be forced to die, unlike most of the pre-revenue field.

Bear case (2–3 permanent-impairment risks). (1) Time + dilution compounding: revenue is a decade out; at +43% share growth/yr, today's holders can be right on the technology and still lose on ownership. (2) First-of-a-kind execution/regulatory risk: no microreactor has ever been licensed and built in the US; the $300–350M/reactor cost is an estimate for a thing never done, and NRC review can slip for years. (3) Governance / related-party fragility: the fuel-cycle thesis rests on LIST, a related, pre-revenue enrichment startup run by the same insiders — if LIST fails or the conflicts unwind, a whole leg of the "vertical integration" story evaporates. Pre-mortem (18 months out, thesis broke): the CPA review added scope and slipped past 2028, another dilutive raise hit at a lower price, the Supermicro MOU never converted, and the stock finished pinned near its net-cash floor — the company survived (cash) but the equity de-rated to "SPAC-like cash shell with a permit pending." Are multiples too high? On any near-term fundamental, infinitely — but the market is (correctly) pricing an option, and after a 68% drawdown the option premium over net cash has compressed to ~$440M. Contrarian view the market is missing: the balance sheet + CPA + litigation-dismissal have quietly turned NNE from "promotional short target" into the most durable survivor in a sector where survival is the scarce asset — the tape is treating it like a dying pre-revenue name while it's actually the one that can't run out of money.

Devil's Advocate (short-seller)

Dismantling the bull case: The whole edifice is narrative + cash, with a decade of execution risk in between, and management whose demonstrated skill is issuing stock, not building reactors. Revenue is concentrated at zero; the "$3.4B DOE program" is a program ceiling awarded to six parties via $2M-minimum task orders, and NNE is a subcontractor to a related party (LIST) — not a contract in hand. The "vertical integration" moat is a stack of MOUs and licenses (UrAmerica, GNS, Supermicro, BEA) — every one non-binding or pre-commercial. The most dangerous competitors bulls underrate: Oklo and X-energy are years ahead, far better capitalized in absolute terms, and backed by Altman/Amazon — if the microreactor market is real, the capital and customers flow to them first. Worst capital-allocation / governance: the LIST related-party web (insiders on both sides), the Yu Option Agreement, contractor-status executives splitting time across mining small-caps, $18.8M/yr SBC, and insider 10b5-1 selling plans set up at the valuation peak — this is the exact pattern Hunterbrook shorted in July 2024 ("no revenue, no products, part-time executives"), and the securities suit (now dismissed on the pleadings, not on the merits of the business) grew from the same soil. What must hold for today's ~$440M EV: that the UIUC permit is granted, that NNE actually funds and builds a $300M+ first-of-a-kind reactor, and that AI-power demand still wants microreactors (vs SMRs or restarts) in the 2030s. If growth/timeline disappoints 20–30%: the option decays toward the ~$11/share net-cash floor — ~40% downside from ~$19. Single permanent-impairment scenario (most plausible): a multi-year NRC delay or a failed/withdrawn LIST enrichment path forces repeated dilutive raises at falling prices, converting the equity into a slowly-bleeding cash shell. Plausibility: moderate and rising the longer revenue stays theoretical.

Management Questions (ordered by information value)

1. The entire fuel-cycle thesis depends on LIST, a related party your Chairman/CFO run — what happens to HALEU Energy Fuel if LIST fails to commercialize laser enrichment, and why is this not an unacceptable single point of failure?
2. Walk through the $300–350M-per-reactor KRONOS estimate — what's funded today, what's the financing plan for the first UIUC unit, and how much dilution should shareholders expect to reach first criticality?
3. What is the specific, defensible timeline from NRC CPA acceptance (May 2026) to construction permit to operating license to first power — and what are the top three schedule risks?
4. The Supermicro MOU is non-binding — what are the concrete conditions and dates that would convert it into a binding, priced offtake, and is there any exclusivity?
5. How do you answer the core short thesis (Hunterbrook) that microreactor licensing takes 10–15 years, not the 2–3 you've implied — what evidence resets that debate?
6. Insiders set up 10b5-1 selling plans near the valuation peak while the company was raising equity — how do you reconcile that with alignment, and what's insider net buying/selling since?
7. With ~56% of market cap in cash, why continue tapping the $400M ATM / $900M shelf rather than pause dilution until milestones re-rate the stock?
8. What is the realistic 2026–2028 revenue path from consulting, ALIP, and the ODIN sale — real dollars, not "opportunities"?
9. What is the status of the Yu Option Agreement and the Canadian Consent Assets today, and will you commit to eliminating founder-affiliated option structures entirely?
10. USNC spent >$120M and still went bankrupt building KRONOS — what specifically is different about your capital and path that avoids the same outcome?
11. How do you compete for customers, capital, and NRC attention against Oklo and X-energy, who are years ahead and far better funded in absolute terms?
12. What triggers an impairment of the $9.08M in-process R&D and the $2.0M LIST investment, and at what point do you write them down?
13. What is the plan to convert executives from independent-contractor status to full-time, and to reduce SBC as a share of spend?
14. Which single 2026–2027 milestone should investors treat as the make-or-break gate for the KRONOS program?
15. If the NRC review slips past 2028, what is your capital and strategy contingency — and at what stock price do you stop issuing equity?

---